FDA Will Propose Drug GMP Quality Management Systems By December
This article was originally published in The Tan Sheet
FDA expects to release a draft on improving the agency's drug GMP management systems by Dec. 1
You may also be interested in...
As a general policy, FDA will not look at process analytical technology research data during drug inspections, FDA New Jersey District Director Douglas Ellsworth asserted during a recent industry-sponsored conference
The cost to pharmaceutical manufacturers of operating process analytical technology often is more than the cost of implementing it, according to Pfizer Drug Product Technology Senior Manager Joep Timmermans
Center for Drug Evaluation & Research Deputy Director Steve Galson, MD, will be acting center director during the period when FDA is expected to announce a decision on forced Rx-to-OTC switches